OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), today announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence.
What This Collaboration Means for the Pharma Market
Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training. Navidence’s platform enables precise definition of health data needs via Computable Operational Definitions (CODefs)—standardized, executable queries that translate complex study criteria (e.g., patient cohorts by diagnosis, treatment, or outcome) into consistent, computable form across datasets.
This collaboration integrates Navidence’s CODefs with the OneMedNet iRWD™ platform powered by Palantir Foundry.
Key integration elements of the collaboration include:
- OneMedNet incorporating Navidence CODefs, to enable consistent cohort, endpoint, and criteria definitions.
- Navidence being integrated with the OneMedNet iRWD™ platform for life sciences, to enable rapid discovery of fit-for-purpose multimodal datasets, streamlining study design regulatory / commercial evidence generation.
Key Potential Benefits of the Collaboration to Our Products and Stakeholders
- Efficiency Gains: Align CODefs with available RWD in near real-time to accelerate study ideation-to-execution and reduce mismatches / rework.
- Cost Savings: Expected to enable precise data matching to avoid over-procuring data sets or pursuing infeasible studies, optimizing R&D budgets.
- Regulatory and Compliance Edge: Combine OneMedNet’s de-identification expertise and Navidence’s standardized definitions to better meet FDA, EMA, and payer requirements for RWE.
- Innovation in Therapeutic Areas: Particularly valuable in complex fields like precision medicine, where imaging RWD (e.g., MRIs, CT scans) combined with CODefs can reveal nuanced insights into disease progression or treatment efficacy.
Expanding Commercial Opportunity
Real-World Data has long been available, but missing efficient, standardized, and scalable access to Real-World Data.
This collaboration is intended to directly advance OneMedNet’s life sciences strategy by addressing core industry demands of faster, more precise and usable data for pharmaceutical and CRO customers, along with expanded opportunities in the rapidly growing RWD market (valued at approximately $1.88 billion in 2025 and projected to reach $6.37 billion by 2034 at 14.54% CAGR),1 enabling access to precisely defined, fit for purpose datasets across:
- Drug development and Life sciences research
- AI model training and validation
- Health economics and outcomes research (HEOR)
- Regulatory-grade evidence generation
- Value-based healthcare analytics
As regulators and payers increasingly require robust real-world evidence, we believe that combining large-scale multimodal data infrastructure with computable definitions positions both companies—and their customers—at the forefront of data transformation.
“Healthcare organizations today have access to more data than ever before and turning that data into reliable evidence requires both scale and precision,” said Aaron Green, CEO & President of OneMedNet. “By combining OneMedNet’s multimodal real-world data platform with Navidence’s computable definitions, we can help researchers identify the right data faster and design studies that deliver high impact evidence.”
“Computable Operational Definitions (CODefs) provide the foundation for consistent and reproducible research independent of the data source,” said Aaron Kamauu, Navidence. “By integrating our content with the OneMedNet iRWD™ platform, researchers can discover precisely defined cohorts and datasets that accelerate study development and improve consistency across clinical research.”
